An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
NovaBay Pharmaceuticals to Present at H.C. Wainwright BioConnect Virtual Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
NovaBay Pharmaceuticals (NYSE American: NBY) will present at the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022. The company aims to provide insights into its expansion strategy following its acquisition of DERMAdoctor in November 2021. CEO Justin Hall projects sales to double in 2022, driven by the transition of Avenova from prescription to over-the-counter sales and plans to launch at least four new products in the first half of 2022. A webcast of the presentation will be available on the company’s website starting January 10, 2022, at 7:00 a.m. Eastern time.
Positive
None.
Negative
None.
Company to provide details on expansion strategy
EMERYVILLE, Calif.--(BUSINESS WIRE)--
NovaBay®Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focused on developing and commercializing scientifically formulated and clinically proven consumer products for the eyecare and skincare markets, announces that management will present a company overview at the H.C. Wainwright BioConnect Virtual Conference being held January 10-13, 2022. A webcast of the NovaBay presentation will be available on the Events page of the company website beginning Monday, January 10, 2022 at 7:00 a.m. Eastern time.
“Our acquisition of DERMAdoctor in November 2021 has created an entirely new company with a dramatically accelerated growth trajectory. We expect sales in 2022 to double from 2021 with a considerably more rapid path to profitability,” said Justin Hall, NovaBay’s CEO. “We’ve had significant success in transitioning Avenova® from prescription-only to over-the-counter sales and are eager to bring that expertise to all existing DERMAdoctor products. Most importantly, expect to leverage DERMAdoctor’s deep expertise in new product development to introduce both new DERMAdoctor and Avenova products, with at least four new products launching in the first half of 2022. I invite you to listen in to hear more details on our plans for significant expansion.”
About NovaBay Pharmaceuticals, Inc.: Going Beyond Antibiotics®
NovaBay Pharmaceuticals, Inc. is a pharmaceutical company that develops and sells scientifically created and clinically proven consumer products for the eyecare and skincare markets. In November 2021, NovaBay acquired DERMAdoctor, LLC, a company offering more than 30 dermatologist-developed skincare products sold through traditional domestic retailers, digital beauty channels and international distributors.
Except for historical information herein, matters set forth in this press release may be forward looking within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial progress and future financial performance of NovaBay Pharmaceuticals, Inc. This release contains forward-looking statements that are based upon management’s current expectations, assumptions, estimates, projections and beliefs. These statements include, but are not limited to, statements regarding our business strategies, current product offerings, marketing efforts, and any potential future product offerings, as well as generally the Company’s expected future financial results. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results or achievements to be materially different and adverse from those expressed in or implied by the forward-looking statements. Factors that might cause or contribute to such differences include, but are not limited to, risks and uncertainties relating to the size of the potential market for our products, the integration of DERMAdoctor’s business into the Company’s business, the possibility that the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, and revenues will not be sufficient to meet the Company’s cash needs. Other risks relating to NovaBay’s business, including risks that could cause results to differ materially from those projected in the forward-looking statements in this press release, are detailed in NovaBay’s latest Form 10-Q/K filings and Registration Statement on Form S-1 filing with the Securities and Exchange Commission, especially under the heading “Risk Factors.” The forward-looking statements in this release speak only as of this date, and NovaBay disclaims any intent or obligation to revise or update publicly any forward-looking statement except as required by law.
Socialize and Stay Informed on NovaBay’s Progress
Like us on Facebook
Follow us on Twitter
Connect with NovaBay on LinkedIn
Visit NovaBay’s Website
Avenova Purchasing Information
For NovaBay Avenova purchasing information:
Please call 800-890-0329 or email sales@avenova.com.
Avenova.com
What is NovaBay's expansion strategy announced in January 2022?
NovaBay Pharmaceuticals announced plans to discuss its expansion strategy at the H.C. Wainwright BioConnect Virtual Conference from January 10-13, 2022, following its acquisition of DERMAdoctor.
How did NovaBay's acquisition of DERMAdoctor impact sales projections for 2022?
CEO Justin Hall stated that NovaBay expects sales to double in 2022 compared to 2021 due to the integration of DERMAdoctor's products.
When will NovaBay launch new products in 2022?
NovaBay plans to introduce at least four new products in the first half of 2022 as part of its strategy post-DERMAdoctor acquisition.
Where can I watch NovaBay's presentation from the H.C. Wainwright BioConnect Conference?
The presentation will be available on NovaBay's Events page starting January 10, 2022, at 7:00 a.m. Eastern time.
What are the key products from NovaBay Pharmaceuticals?
NovaBay Pharmaceuticals primarily focuses on Avenova and DERMAdoctor products, which are scientifically formulated for eyecare and skincare.
